An effective DNA priming-protein boosting approach for the cervical cancer vaccination.
Considerable advances have been made in developing human papillomaviruses (HPV) prophylactic vaccines based on L1 virus-like particles (VLPs). However, there are limitations in the availability of these vaccines in developing countries, where most cases of cervical cancer occur. In the current study, the prime-boost immunization strategies were studied using a DNA vaccine carrying HPV-16 L1 gene (pcDNA/L1) and insect cell baculovirus-derived HPV-16 L1 VLP. The humoral immunity was evaluated by measuring the specific IgG levels, and the T-cell immune response was assessed by measuring different cytokines such as IFN-γ, TNF-α and IL-10. Results showed that although immunization with pcDNA/L1 alone could induce strong cellular immune responses, higher immunogenicity especially antibody response was achieved in pcDNA/L1 priming-VLP boosting regimen. Therefore, we suggest that prime-boost regimen can be considered as an efficient prophylactic and therapeutic vaccine.
Immunology Lab, Institute of Biochemistry and Biophysics, University of Tehran, Tehran, Iran, P.O. Box 131451384.
Zahra
Z
Kianmehr
Immunology Lab, Institute of Biochemistry and Biophysics, University of Tehran, Tehran, Iran, P.O. Box 131451384.
Susan K
SK
Ardestani
Department of Virology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran, P.O. Box 14115111.
Hoorieh
H
Soleimanjahi
Influenza Research Lab, Department of Virology, Pasteur Institute of Iran, Tehran, Iran P.O. Box 1316943551.
Behrokh
B
Farahmand
Department of Virology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran, P.O. Box 14115111.
Asghar
A
Abdoli
Production and Research complex, Pasteur Institute of Iran, Karaj, Iran P.O. Box 3159915111.
Maryam
M
Khatami
Influenza Research Lab, Department of Virology, Pasteur Institute of Iran, Tehran, Iran P.O. Box 1316943551.
Khadijeh
K
Akbari
Influenza Research Lab, Department of Virology, Pasteur Institute of Iran, Tehran, Iran P.O. Box 1316943551 fotouhi@pasteur.ac.ir.
Fatemeh
F
Fotouhi
D000818:Animals; D000914:Antibodies, Viral / Q000097:blood; D036022:Capsid Proteins / Q000235:genetics / Q000276:immunology*; D016207:Cytokines / Q000378:metabolism; D005260:Female; D007074:Immunoglobulin G / Q000097:blood; D008810:Mice, Inbred C57BL; D009856:Oncogene Proteins, Viral / Q000235:genetics / Q000276:immunology*; D053918:Papillomavirus Vaccines / Q000008:administration & dosage / Q000276:immunology*; D013601:T-Lymphocytes / Q000276:immunology; D002583:Uterine Cervical Neoplasms / Q000276:immunology / Q000517:prevention & control*; D014611:Vaccination / Q000379:methods*; D019444:Vaccines, DNA / Q000008:administration & dosage / Q000276:immunology*; D022223:Vaccines, Subunit / Q000008:administration & dosage / Q000276:immunology; D014614:Vaccines, Synthetic / Q000008:administration & dosage / Q000276:immunology; D058425:Vaccines, Virus-Like Particle / Q000008:administration & dosage / Q000276:immunology*
D000914:Antibodies, Viral; D036022:Capsid Proteins; D016207:Cytokines; D007074:Immunoglobulin G; D009856:Oncogene Proteins, Viral; D053918:Papillomavirus Vaccines; D019444:Vaccines, DNA; D022223:Vaccines, Subunit; D014614:Vaccines, Synthetic; D058425:Vaccines, Virus-Like Particle; C063317:L1 protein, Human papillomavirus type 16
DNA vaccine; HPV-16; VLPs; immune response; prime-boost regimen; prophylactic vaccine